RxDoctor Payments Data

Barry Liberoni, MD

Internal Medicine · Bay City, TXNPI 1861470361

Payments from drug & device makers

$8,270in general payments, 2019–2025

Across 432 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$517
  • AbbVie$427
  • Amgen$415
  • Corcept Therapeutics$396
  • Pfizer$359
  • plus $4K from 52 others

What the payments were for

  • Food & beverage$7,96896%
  • Education$3014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca99$1,978
Novo Nordisk24$517
AbbVie(2 entities)27$427
Amgen(2 entities)22$415
Corcept Therapeutics18$396
Pfizer19$359
Eisai Inc.19$305
Axsome Therapeutics, Inc.10$257
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$256
Boehringer Ingelheim11$221
Bayer11$209
Arbor Pharmaceuticals, Inc.15$202
Jazz Pharmaceuticals Inc.8$183
Biohaven Pharmaceutical Holding Company Ltd.9$179
Antares Pharma, Inc.11$177
Astellas Pharma US Inc6$169
Lilly USA, LLC10$160
Shield Therapeutics Inc7$121
Merck6$103
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$102
Novartis6$97
Esperion Therapeutics, Inc.5$95
Takeda Pharmaceuticals U.S.A., Inc.6$90
Gilead3$85
Ironwood Pharmaceuticals, Inc4$71
Currax Pharmaceuticals LLC4$71
Kowa Pharmaceuticals America, Inc.5$69
GSK4$65
Insulet Corporation1$54
Xeris Pharmaceuticals, Inc.3$51
Hikma Pharmaceuticals USA2$47
Genentech USA, Inc.2$44
Biohaven Pharmaceuticals, Inc.2$44
Baxter Healthcare2$39
Dexcom, Inc.2$38
Regeneron Healthcare Solutions, Inc.2$38
Exact Sciences2$36
Halozyme Inc2$36
Verity Pharmaceuticals Inc.2$35
Medtronic2$34
Paratek Pharmaceuticals, Inc.2$30
Boston Scientific1$29
Idorsia Pharmaceuticals US Inc2$28
Organon1$27
Sanofi-aventis U.S. LLC2$27
Ascendis Pharma Endocrinology Inc1$27
Lundbeck LLC1$27
GRT US Holding, Inc.1$25
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$24
Eyevance Pharmaceuticals LLC1$23
Viatris Specialty LLC1$23
Kyowa Kirin, Inc.1$17
Bardy Diagnostics, Inc.1$15
Assertio Therapeutics, Inc.1$15
E.r. Squibb & Sons, L.L.C.1$15
Otsuka America Pharmaceutical, Inc.1$14
Cequr Corporation1$13
Johnson & Johnson1$13

How this compares

$8,270 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$513,895
Medicare patients
495
Services billed
7,812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide514$592,165
OzempicSemaglutide280$299,107
FarxigaDapagliflozin Propanediol155$156,847
EliquisApixaban156$151,321
JardianceEmpagliflozin93$135,779
Repatha SureclickEvolocumab149$114,327
Trelegy ElliptaFluticasone/Umeclidin/Vilanter107$89,747
Synjardy XrEmpagliflozin/Metformin Hcl80$86,921
Tresiba Flextouch U-200Insulin Degludec83$67,166
Trijardy XrEmpaglifloz/Linaglip/Metformin59$66,655
ZenpepLipase/Protease/Amylase15$61,085
Xigduo XrDapaglifloz Propaned/Metformin65$51,526
JanuviaSitagliptin Phosphate46$46,532
EntrestoSacubitril/Valsartan51$45,917
XareltoRivaroxaban39$45,371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$160$592,165514 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Glyxambi, Tradjenta$221$348,338310 claims
Novo NordiskOzempic, Rybelsus$517$336,387310 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$1,978$195,062210 claims
PfizerEliquis$359$151,321156 claims
MerckJanuvia, Janumet, Janumet Xr$103$95,95198 claims
GSKTrelegy Ellipta$65$89,747107 claims
NovartisEntresto$97$45,91751 claims
Johnson & JohnsonXarelto$13$45,37139 claims
Astellas Pharma US IncMyrbetriq$169$42,87571 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$90$42,73259 claims
AbbVieLinzess, Synthroid$427$37,384110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Bay City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →